Re­gen­eron looks to George Yan­copoulos' R&D arm — and part­ners — in hunt for its next big cash cows

Re­gen­eron R&D chief and co-founder George Yan­copou­los has nev­er been shy about tout­ing the com­pa­ny’s re­search ca­pa­bil­i­ties — or am­bi­tions. But then, he’s al­so a stand­out in his field, some­one who can back up the bold talk with the rep he has built for herd­ing a block­buster group of cash cow fran­chis­es through the pipeline.

Dur­ing the big biotech’s quar­ter­ly up­date to­day, CEO Len Schleifer was on hand to tout their con­tin­ued mar­ket growth for Eylea — a $5.8 bil­lion be­he­moth with a Phase III read­out loom­ing for their 8 mg ver­sion — as well as the Sanofi-part­nered Dupix­ent with a big boost from a Covid-19 an­ti­body now side­lined by Omi­cron. But Yan­copou­los stole the show, en­thu­si­as­ti­cal­ly high­light­ing a range of ef­forts in the re­search group that has the po­ten­tial to cre­ate game-chang­ing med­i­cines that can gen­er­ate bil­lions more for the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER